Research Papers:

The impact of interleukin-10 (IL-10) gene 4 polymorphisms on peripheral blood IL-10 variation and prostate cancer risk based on published studies

Tingting Men, Cuicui Yu, Dan Wang, Fang Liu, Jingjing Li, Xiaoying Qi, Chunhua Yang, Wenguo Jiang, Xiaodan Wei, Xuri Li, Bin Wang, Jia Mi and Geng Tian _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:45994-46005. https://doi.org/10.18632/oncotarget.17522

Metrics: PDF 1236 views  |   HTML 2403 views  |   ?  


Tingting Men1,*, Cuicui Yu2,*, Dan Wang3, Fang Liu3, Jingjing Li3, Xiaoying Qi3, Chunhua Yang3, Wenguo Jiang3, Xiaodan Wei3, Xuri Li3, Bin Wang4, Jia Mi3 and Geng Tian3

1School of Nursing, Binzhou Medical University, Yantai, Shandong, China

2Department of Anesthesiology, Yantai Yu Huang Ding Hospital, Yantai, Shandong, China

3Medicine and Pharmacy Research Center, Binzhou Medical University, Yantai, Shandong, China

4Institute of Molecular Imaging, Binzhou Medical University, Yantai, Shandong, China

*These authors have contributed equally to this work

Correspondence to:

Geng Tian, email: [email protected]

Jia Mi, email: [email protected]

Bin Wang, email: [email protected]

Keywords: prostate cancer, interleukin-10, polymorphism, peripheral blood interleukin-10, meta-analysis

Received: December 16, 2016     Accepted: April 11, 2017     Published: April 29, 2017


This study purported to investigate the impact of interleukin-10 (IL-10) gene 4 polymorphisms (-1082G>A, -819T>C, -592A>C and 210T>C) on peripheral blood IL-10 variation and prostate cancer (PCa) risk, with a special consideration given to various origins of between-study heterogeneity. 2 researchers independently fulfilled literature retrieval, quality assessment and information collection. Sub-grouped analyses per ethnicity, continent, design type, control source, genotyping procedure, genotype validation, age-matched status, study sample size, quality score and controls’ mean age were conducted, respectively. Total 17 unduplicated studies (patients/controls: 7561/8101) were assessable for PCa risk, and 4 unduplicated studies (1189 subjects) for peripheral blood IL-10 variation. Pooling all assessable studies identified a marginally significant association between the -1082A allele and increased PCa risk (odds ratio (OR)=1.10, 95% confidence interval [CI]: 1.00 to 1.21) (Heterogeneity I2=64.3%), and no significance was detected in sub-grouped analyses of this polymorphism. Contrastingly, the -592C allele was significantly associated with reduced PCa risk in both prospective (OR=0.85, 95% CI: 0.77 to 0.95) and population-based (OR=0.92, 95% CI: 0.84 to 1.00) studies (Heterogeneity I2=0.0% and 18.1%). Moreover, carriers of combined -592CA/CC genotypes had a significant higher level of peripheral blood IL-10 than the -592AA genotype carriers (weighted mean difference=0.45 and 0.54 mg/dL, 95% CI: 0.23 to 0.67 and 0.30 to 0.39). The above comparisons possessed a low probability of publication bias. In sum, our findings suggested that IL-10 gene -592A>C polymorphism may represent a promising candidate locus for the occurrence of PCa, and further signified a contributing role of this polymorphism in prostate carcinogenesis.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 17522